China
Africa
Explore chapters and articles related to this topic
Greece and Rome
Published in Michael J. O’Dowd, The History of Medications for Women, 2020
The great university and library of Alexandria were founded in 331 BC and Greek culture and science became firmly established in Egypt. A school of Empirics, who rejected all a priori knowledge, and relied solely on trial and experience, developed there in the second century BC. Its members experimented with medicinal drugs and toxicology. Mithridates VI (reigned from 120–63 BC), king of Pontus, in Asia Minor, was said to have developed the art of taking poisons without adverse outcome. He protected himself against the toxic effects of plants by developing a universal antidote, thereafter known as a ‘mithridate’ or ‘theriac’ (a mixture of medicines honey and other constituents later known as ‘treacle’).
The Management of Obstetric Complications
Published in Audrey Eccles, Obstetrics and Gynaecology in Tudor and Stuart England, 2018
In all these cases, and often when more serious complications arose, expulsive or cordial medicines were relied on, and some people still had faith in such medicines in the eighteenth century, though the better obstetricians used them less and less. Mauriceau said mithridate and treacle ought not to be given to women in difficult labour, but rather good nourishment that would ‘comfort the Stomach, without nauseating it, as those Drugs do which are only good for them that sell them’.1
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera
Published in Expert Review of Hematology, 2023
Ivan Krecak, Marko Skelin, Srdan Verstovsek
On the basis of the RESPONSE trial [41], the United States (US) Federal Drug Administration (FDA) approved ruxolitinib as a second-line treatment for HU-intolerant/resistant PV patients in 2014. Long-term follow-up also confirmed that ruxolitinib may provide durable and effective HCT control, alleviate the need for phlebotomies, and significantly improves splenomegaly, disease-related symptoms, and the overall quality of life in PV patients not responding to or intolerant of HU [42–44]. However, despite multiple clinical benefits observed with ruxolitinib, it is not yet clear whether ruxolitinib possess disease-modifying abilities [1]. A few studies demonstrated that ruxolitinib decreased the thromboembolic events compared to best available treatment (BAT) in PV patients [44–47].; however, a meta-analysis showed that although the reported thrombotic events were consistently lower with ruxolitinib versus BAT in PV patients, the difference between ruxolitinib and BAT did not reach statistical significance globally [48]. Ruxolitinib is currently being tested as the first-line treatment of high-risk PV and ET patients in the Ruxo-BEAT (NCT02577926) and also for the first-line treatment of high-risk PV in the MITHRIDATE clinical trial (NCT 04116502).